Electra Therapeutics
A unique vision on mastering SIRP. A new way to change lives.
A unique vision on mastering SIRP. A new way to change lives.
Electra Therapeutics is a clinical stage biotechnology company founded in 2018. They specialize in developing therapies that target signal regulatory proteins (SIRP) for the treatment of immunological diseases and cancer. Their recent milestone includes an impressive $84.00M Series B investment on 16 February 2022. This significant funding round involved a consortium of high-profile investors including New Leaf Venture Partners, RA Capital Management, OrbiMed, Redmile Group, Cowen Digital, Westlake Village BioPartners, and Cormorant Asset Management.
Electra Therapeutics' slogan, "A unique vision on mastering SIRP. A new way to change lives.", reflects their innovative approach and strong commitment to making a transformative impact in the biotechnology and healthcare industries.
As a promising player in the biotech landscape, Electra Therapeutics' targeted focus on SIRP therapies positions them favorably for potential growth and success in addressing critical unmet medical needs.
| Funding Stage | Amount | No. Investors | Investors | Date |
|---|---|---|---|---|
| Series B | $84.00M | 7 |
|
16 Feb 2022 |
| Series A | $16.00M | - | 04 Dec 2018 |
No recent news or press coverage available for Electra Therapeutics.
We care about your data, and we'd love to use cookies make your experience better.